Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. (23rd February 2018)

• Record Type: Journal Article
• Authors: Trivedi, Palak J; Adams, David H
• Is Part Of: Journal of Crohn's and colitis. Volume 12(2018:Aug.)Supplement 2
• Page Start: S641
• Page End: S652
• Publication Date: 2018-02-23
• Subjects: Eldelumab -- Mongersen -- Vercirnon; Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjx145
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: The principal targets for anti-chemokine therapy in inflammatory bowel disease (IBD) have been the receptors CCR9 and CXCR3 and their respective ligands CCL25 and CXCL10. More recently CCR6 and its ligand CCL20 have also received attention, the expression of the latter in enterocytes being manipulated through Smad7 signalling. These pathways, selected based on their fundamental role in regulating mucosal immunity, have led to the development of several therapeutic candidates that have been tested in early phase clinical trials with variable clinical efficacy. In this article, we appraise the status of chemokine-directed therapy in IBD, review recent developments, and nominate future areas for therapeutic focus.